GPhA Waxman/Hatch Plan Would Use Bonds To Protect 180-Day Exclusivity
Executive Summary
The Generic Pharmaceutical Association is proposing to change the Waxman/Hatch patent challenge process to use bonds posted by brand name companies as a substitute for market exclusivity to provide an incentive for generic companies.
You may also be interested in...
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.